Basic Information
| LncRNA/CircRNA Name | H19 |
| Synonyms | H19, ASM, ASM1, BWS, D11S813E, LINC00008, NCRNA00008, WT2 |
| Region | GRCh38_11:1995176-2001470 |
| Ensemble | ENSG00000130600 |
| Refseq | NR_002196 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | breast cancer |
| ICD-0-3 | C50 |
| Methods | qPCR etc. |
| Sample | cell lines (HCC1937 and HCC38) |
| Expression Pattern | up-regulated |
| Function Description | Network analysis revealed the existence of five genes related with H19,including miR-103, miR-107, let-7, miR-29b-1, and Trx. In-vitro analysis showed that suppression of H19 using siRNA reduces sphere formation capacity in both HCC1934 and iCSCL10A cell lines.In clinical studies, H19 expression was associated with hormone negativity, tumor size, and nodal status.Patients with H19 expression had significantly poor disease-free survival (DFS) and overall survival(OS). The effect of H19 expression on prognosis was the most significant in triple-negative breast cancer compared to that in other subtypes. |
| Pubmed ID | 29693231 |
| Year | 2018 |
| Title | LncRNA H19 is associated with poor prognosis in breast cancer patients and promotes cancer stemness. |
External Links
| Links for H19 | GenBank HGNC NONCODE |
| Links for breast cancer | OMIM COSMIC |